At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 13 enrolled
Drug / intervention
Losartandrug
Likely dose
Losartan 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-Inflammatory Therapy to Augment CFTR Rescue in CF Patients
In Brief
A Early Phase 1 clinical trial evaluating Losartan for Cystic Fibrosis. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartFeb 2022
Primary CompletionSep 2025
Study CompletionMar 2026
TodayJul 2026
First PostedFeb 19, 2018
Enrollment StartFeb 15, 2022
Primary CompletionSep 3, 2025
Study CompletionMar 31, 2026
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.4 years ago
Interventions
Losartandrug
50 mg/day for 7 days followed by 100 mg/day for 12 weeks